□□□□□□□□□□□□□□ □□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□ □□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□Professor Associate Professor 植山（鳥羽） 由希子 Assistant Professor 教 授 水口 裕之 准教授 清水かほり 助 教 Hiroyuki MIZUGUCHI 06-6879-8185 mizuguch@phs.osaka-u.ac.jp06-6879-8188 Kahori SHIMIZU Yukiko UEYAMA-TOBA 06-6879-8187 Fax 06-6879-81871）ヒト iPS 細胞から肝臓細胞、小腸上皮細胞等への分化制御に関する分子生物学的解析やオルガノイド培養系を用いた創薬研究・再生医療研究への応用2）新規遺伝子導入・発現制御技術の開発と遺伝子治療、再生医療、ワクチン、ウイルス療法等への応用3）ノンコーディング RNA（マイクロ RNA 等）の機能解析と生命科学研究への応用4）ゲノム編集技術の開発と遺伝子治療、幹細胞研究への応用shimizu@phs.osaka-u.ac.jptoba-y@phs.osaka-u.ac.jp教 授 水口 裕之1. Inui T. et al., Functional intestinal monolayers from organoids derived from human iPS cells for drug discovery research. Stem Cell Res. Ther., 15, 57 (2024)2. Ueyama-Toba Y. et al., Development of a hepatic differentiation method in 2D culture from primary human hepatocyte-derived organoids for pharmaceutical research. iScience, 27, 110778 (2024)3. Onishi R. et al., Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5. Int. J. Pharm., 662, 124480 (2024)4. Sakurai F. et al., Transplacental delivery of factor IX Fc-fusion protein ameliorates bleeding phenotype of newborn hemophilia B mice. J. Contl. Rel. 24, 415-424 (2024) 5. Shintani T., et al., Establishment of UGT1A1-knockout human iPS-derived hepatic organoids for UGT1A1-specific kinetics and toxicity evaluation. 6. Sakai E., et al., miR-27b targets MAIP1 to mediate lipid accumulation in cultured human and mouse hepatic cells. Communi. Biol., 6, 669 (2023)7. Yamashita T. et al., Monolayer platform using human biopsy-derived duodenal organoids for pharmaceutical research. Mol. Ther. Methods. Clin. Dev., 22, 263-278 (2021)8. Deguchi S. et al., In vitro model for a drug assessment of cytochrome P450 family 3 subfamily A member 4 substrates using human induced pluripotent stem cells and genome editing technology. Hepatol. Commun., 5, 1385-1399 (2021)9. Shimizu K. et al., Adenovirus vector-induced IL-6 promotes leaky adenoviral gene expression, leading to acute hepatotoxicity. J. Immunol., 206, 410-421 (2021)10.Ono R. et al., Efficient antitumor effects of a novel oncolytic adenovirus fully composed of species B adenovirus serotype 35. Mol. Ther. Oncolysis., 20, 399-409 (2021) 11.Takayama K. et al., Generation of human iPS cell-derived intestinal epithelial cell monolayers by CDX2 transduction. Cell. Mol. Gastroenterol. Hepatol., 8, 513-526 (2019)12.Takayama K. et al., Prediction of inter-individual differences in hepatic functions and drug sensitivity by using human iPS-derived hepatocytes. Proc. Natl. Acad. Sci. USA., 111, 16772-16777 (2014)13.Blumberg R. et al., Protective mucosal immunity mediated by epithelial CD1d and IL-10, Nature, 509, 497-502 (2014)Mol. Ther. Methods. Clin. Dev.,30, 429-442 (2023)□□□□□□□ Biochemistry and Molecular Biology
元のページ ../index.html#9